Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 241Lymphoma 178Lymphoma, Large B-Cell, Diffuse 172Precursor Cell Lymphoblastic Leukemia-Lymphoma 88Lymphoma, Follicular 79Lymphoma, Non-Hodgkin 73Burkitt Lymphoma 66Multiple Myeloma 64Leukemia 58Hodgkin Disease 45Lymphoma, Mantle-Cell 41Neoplasms 35Lymphoma, T-Cell, Peripheral 31Lymphoma, B-Cell 30Lymphoma, B-Cell, Marginal Zone 28Lymphoma, Large-Cell, Anaplastic 26Neoplasm Metastasis 25Lymphoma, Large-Cell, Immunoblastic 24Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 22Leukemia, Lymphocytic, Chronic, B-Cell 22Neoplasms, Plasma Cell 21Recurrence 20Immunoblastic Lymphadenopathy 15Dendritic Cell Sarcoma, Interdigitating 15Lymphoma, T-Cell 14Leukemia, Biphenotypic, Acute 10Waldenstrom Macroglobulinemia 9Blast Crisis 9Primary Myelofibrosis 8Myelodysplastic Syndromes 8

Interventions

Triptorelin Pamoate 1Prednisone 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoadjuvant Therapy \ High Risk Prostate Cancer \ Docetaxel × Prednisone × Clear all
NCT04869371 2022-12-29

Androgen Deprivation Therapy Combined With Docetaxel for High Risk Prostate Cancer

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Phase 2 Unknown
75 enrolled
Genitourinary

Neoadjuvant Therapy \ High Risk Prostate Cancer \ Docetaxel

Data powered by HemOnc (CC BY 4.0) Colophon âš¡